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Abstract
Background: The bone marrow (BM) cytokine milieu might substantially affect T-lymphocyte homeostasis in HIV-positive
individuals. Interleukin-7 (IL-7) is a bone marrow-derived cytokine regulating T-cell homeostasis through a CD4+-driven
feedback loop. CD4+ T-lymphopenia is associated with increased free IL-7 levels and reduced IL-7R expression/function,
which are only partially reverted by highly active antiretroviral therapy (HAART). We investigated the BM production,
peripheral expression and signaling (pStat5+ and Bcl-2+ CD4+/CD8+ T cells) of IL-7/IL-7Ra in 30 HAART-treated HIV-positive
patients who did not experience CD4+ recovery (CD4+ #200/ml) and who had different levels of HIV viremia; these patients
included 18 immunological nonresponders (INRs; HIV-RNA#50), 12 complete failures (CFs; HIV-RNA.1000), and 23 HIV-
seronegative subjects.
Methods: We studied plasma IL-7 levels, IL-7Ra+CD4+/CD8+ T-cell proportions, IL-7Ra mRNA expression in PBMCs,
spontaneous IL-7 production by BM mononuclear cells (BMMCs), and IL-7 mRNA/IL-7Ra mRNA in BMMC-derived stromal cells
(SCs). We also studied T-cell responsiveness to IL-7 by measuring the proportions of pStat5+ and Bcl-2+ CD4+/CD8+ T cells.
Results: Compared to HIV-seronegative controls, CFs and INRs presented elevated plasma IL-7 levels and lower IL-7Ra
CD4+/CD8+ cell-surface expression and peripheral blood production, confirming the most relevant IL-7/IL-7R disruption.
Interestingly, BM investigation revealed a trend of higher spontaneous IL-7 production in INRs (p = .09 vs. CFs) with a
nonsignificant trend toward higher IL-7-Ra mRNA levels in BMMC-derived stromal cells. However, upon IL-7 stimulation, the
proportion of pStat5+CD4+ T cells did not increase in INRs despite higher constitutive levels (p = .06); INRs also displayed
lower Bcl-2+CD8+ T-cell proportions than controls (p = .04).
Conclusions: Despite severe CD4+ T-lymphopenia and a disrupted IL-7/IL-7R profile in the periphery, INRs display elevated
BM IL-7/IL-7Ra expression but impaired T-cell responsiveness to IL-7, suggesting the activity of a central compensatory
pathway targeted to replenish the CD4+ compartment, which is nevertheless inappropriate to compensate the
dysfunctional signaling through IL-7 receptor.
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Introduction
Interleukin-7 (IL-7) is a type-1 stromally produced cytokine that
plays a crucial role for T cell biology, enhancing thymocyte
production [1,2], ‘‘homeostatic’’ proliferation, survival of memory
and naı¨ve peripheral T cells [3,4], type-1 immune responses and
CD8+ T-cell cytotoxicity [5]. IL-7 signals through the IL-7
receptor (IL-7R) comprising an IL-7-specific-a-chain (IL-7Ra) and
a common c-chain (cc) expressed on thymocytes, T lymphocytes,
and bone marrow (BM) macrophages. Downstream IL-7 signaling
involves Janus kinase 1 (Jak1), Jak3, Src kinases, phosphatidylino-
sitol-3 kinase (PI3K), signal transducer and activator of transcrip-
tion 3 (Stat3) and Stat5. The survival function of IL-7 is largely
mediated through the maintenance of a favorable balance of anti-
apoptotic Bcl-2 family members [6].
In several lymphopenic conditions, the IL-7/IL-7R axis has been
shown to be crucial in sustaining peripheral T-cell homeostasis via a
rise in circulating IL-7 levels that acts as a survival signal to both
lymphoid progenitors and mature circulating T lymphocytes [7,8].
In line with this model, CD4+ T-lymphopenia in the course of HIV
disease is characterized by a substantial increase in IL-7 plasma
levels, and yet such an IL-7-enriched milieu fails to preserve the
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peripheral T-cell pool. Aside from the immunodestructive effects of
HIV-1, a major cause of the failure of IL-7 to sustain peripheral T-
lymphocyte homeostasis might be the down-regulation of IL-7Rca
expression and suppression of IL-7Ra function on peripheral T
lymphocytes [9,10,11], which might counteract the positive effect of
IL-7 on T-cell homeostasis.
CD4+ T-cell reconstitution following the initiation of highly
active antiretroviral therapy (HAART) is associated with a
normalization of the IL-7/IL-7R axis that comprises reduced
circulating IL-7 and increased IL-7Ra expression on T cells,
although the levels seen in healthy HIV-seronegative individuals
are not reached. However, the altered responsiveness of T cells to
IL-7 has been demonstrated in HAART-treated patients,
suggesting the persistence of IL-7/IL-7R dysfunction [9,10,11].
Despite the fact that the majority of patients undergoing HAART
undergo full viro-immunologic reconstitution, up to 30% of
individuals fail to experience peripheral CD4+ T-cell rescue with
either suppressed or unsuppressed viremia and have an increased
rate of clinical progression [12,13,14,15]. Most recently, inefficient
CD4+ gain on HAART has been associated with reduced recovery
of T-cell responsiveness to IL-7 [16,17]. Furthermore, patients with
failed CD4+ recovery on HAART display specific alterations in the
bone marrow, the primary organ contributing to IL-7 synthesis,
which includes altered clonogenic capability, stromal cell dysfunc-
tion and imbalanced cytokine milieu [18,19].
Collectively, these findings suggest a crucial influence of the IL-
7/IL-7R axis on CD4+ T-lymphocyte reconstitution, and yet the
reciprocal interactions of IL-7/IL-7R expression within lymphoid
organs and peripheral blood are still poorly understood. The levels
of circulating IL-7 might either reflect changes in cytokine
production at IL-7-producing sites via a feedback loop with
peripheral T-cell pool [1] or follow the dynamics of IL-7Ra cell-
surface expression [20,21]. Analogously, the level of IL-7Ra
expression is regulated by both the free IL-7 level [11,22] and
HIV-mediated effects [23,24].
We aimed to comprehensively investigate the production,
peripheral dynamics and function of IL-7/IL-7R in HIV-positive
patients failing to recover CD4+ counts following initiation of
HAART. In particular, as HIV antigenemia has been shown to
affect both bone marrow function and IL-7R peripheral expression
[24,25], we reasoned that HAART-treated lymphopenic patients
with full viremia suppression (immunological nonresponders, INRs)
might feature a different IL-7/IL-7R profile than individuals with
complete immune-virological failure (complete failure, CFs).
Results
Patient characteristics
Thirty HIV-positive patients were recruited: 18 INRs and 12
CFs. Subjects were comparable with respect to age, sex, risk
factors for HIV, AIDS diagnosis, and HAART length and
regimen at the time of analysis (Table 1).
As per inclusion criteria, CFs displayed significantly higher
mean HIV RNA levels (p = .0001) and comparable mean absolute
and percent current CD4+ counts (p = .4) and nadir (p = .2)
(Table 1). No differences were shown with respect to HAART
regimen and duration between the groups; 83% of the patients
(25/30) were on a protease inhibitor (PI)-based regimen (Table 1).
INRs had high circulating IL-7 levels and low IL-7Ra
expression on T cells
Compared to HIV-seronegative subjects, HIV-positive patients
had significantly higher mean IL-7 plasma levels (HIV positive:
764.7 pg/ml, HIV seronegative: 3.362.4 pg/ml, p = .002)
(Figure 1A), with elevated circulating IL-7 levels in both INRs
and CFs, reaching significance for CFs (INRs: 6.365.1 pg/ml;
CFs: 7.564.6 pg/ml; p = .7 for INRs vs. CFs; p = .1 for INRs vs.
HIV-seronegative subjects; p = .003 for CFs vs. HIV-seronegative
subjects) (Figure 1A).
As for IL-7Ra expression, HIV-positive patients had significant
lower mean CD4+/CD8+ CD127+ T-cell proportions
(CD4+CD127+, HIV positive: 62.7626.4%, HIV seronegative:
88.668.4%, p = .0001; CD8+CD127+, HIV positive:
39.4625.1%, HIV seronegative: 80618.6%; p = .0001;
Figure 1B–C). INRs displayed significantly lower levels of
CD4+CD127+ T cells than HIV-seronegative subjects and levels
comparable to those of CFs (INRs: 63.1629.1%; CFs: 62.4624.7;
p = .99 for INRs vs. CFs; p = .02 for INRs vs. HIV-seronegative
subjects; p = .002 for CFs vs. HIV-seronegative subjects)
(Figure 1B). A similar trend was shown for CD8+ IL-7Ra
expression (INRs: 38.8614.2%; CFs: 39.9632.2%; p = .99 for
INRs vs. CFs; p = .0001 for INRs vs. HIV-seronegative subjects,
p = .001 for CFs vs. HIV-seronegative subjects) (Figure 1C).
INRs had reduced IL-7Ra expression by PBMCs
According to cell-surface expression, HIV-positive patients
presented significantly lower IL-7Ra mRNA levels than HIV-
seronegative subjects (HIV positive: 138.76109.9; HIV seroneg-
Table 1. Patients’ characteristics.
Characteristics INRs (n=18) CFs (n =12) P
Age, years* 4768 4369 0.278
Sex6
Male
Female
15 (83)
3 (17)
11 (92)
1 (8)
0.632
Risk Factors61
TD
ES
Other
3/16 (19)
11/16 (69)
2/16 (32)
4/10 (40)
4/10 (40)
2/10 (20)
0.343
Time from HIV diagnosis,
years*
566 865 0,229
Previous AIDS diagnosis6
yes
12 (67) 8 (67) 1.000
Current CD4/mL* 143684 1846164 0.448
Current CD4%* 1366 18616 0.324
Nadir CD4/mL* 59653 1066112 0.171
Nadir CD4%* 665 667 0.971
Current HIV RNA,
log10 cp/mL*
1.860 3.961.3 0.0001
HAART regimen6
2NRTI+1PI
2NRTI+1NNRTI
Other:
(1NRTI+1NNRTI+1PI
1NRTI+1PI+raltegravir
3NRTI+1PI+enfuvirtide
14 (78)
2 (11)
2 (11)
1
0
1
8 (67)
2 (17)
2 (17)
1
1
0
0.844
HAART length, months* 29632 57639 0.098
NOTE. INRs, Immunologic Non Responders: HIV-RNA,50 cp/mL, CD4#200/mL;
CFs, Complete Failures: HIV-RNA.100 cp/mL, CD4#200/mL.
*Data are mean 6 standard deviation;
u data are n (%).
1Risk factor for HIV infection was available in 16 out of 18 INRs and in 10 out of
12 CFs. HAART, Highly Active Antiretroviral Therapy. NRTI, nucleoside reverse-
transcriptase inhibitor; NNRTI, nonnucleoside reverse-transcriptase inhibitor; PI,
protease inhibitor.
doi:10.1371/journal.pone.0015663.t001
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ative: 625.36434.8 ng IL-7Ra/10 ng GAPDH; p = .03)
(Figure 1D). Furthermore, both INRs and CFs had significantly
lower PBMC IL-7Ra mRNA levels vs. HIV-seronegative controls
(INRs: 163.36120.2 ng IL-7 Ra/10 ng GAPDH; CFs:
101.7695.7 ng IL-7 Ra/10 ng GAPDH; p = .6 for INRs vs.
CFs; p = .04 for INRs vs. HIV-seronegative subjects; p = .03 for
CFs vs. HIV-seronegative subjects) (Figure 1D).
INRs displayed augmented IL-7/IL-7Ra expression in
bone marrow mononuclear cell (BMMC) cultures
Having shown differences in IL-7/IL-7Ra expression and
production in peripheral blood, we investigated the expression at
the bone marrow level. According to data for the periphery,
HIV-positive patients as a whole presented a trend toward higher
IL-7 levels in BMMC supernatants compared to HIV-seroneg-
ative subjects, though the difference was not statistically
significant (HIV positive: 2.867.7 pg/ml, HIV seronegative:
0.560.4 pg/ml; p = .7) (Figure 2A). Interestingly, following the
division patient into groups, INRs showed the highest level of
spontaneous BMMC IL-7 production (INRs: 5.1610.7 pg/ml,
CFs: 0.560.8 pg/ml; p = .09 for INRs vs. CFs; p = .4 for INRs vs.
HIV-seronegative subjects; p = 1 for CFs vs. HIV-seronegative
subjects) (Figure 2A).
Real-time PCR analysis of BMMC-derived SCs revealed
comparable IL-7 mRNA levels between HIV-positive patients
and HIV-seronegative subjects (HIV positive: 74.56100.7 ng IL-
7/10 ng GAPDH; HIV seronegative: 59.36113.3 ng IL-7/10 ng
GAPDH; p = .4). Interestingly, INRs had a higher mean IL-7
mRNA level than CFs and HIV-seronegative subjects, but this
difference was not statistically significant (INRs: 93.66118.2 ng of
IL-7/10 ng GAPDH, CFs: 36.2641 ng of IL-7/10 ng GAPDH;
p = .5 for CFs vs. INRs; p = .8 for INRs vs. HIV-seronegative
subjects; p = .9 for CFs vs. HIV-seronegative subjects) (Figure 2B).
Furthermore, BMMC-derived SCs were investigated for IL-
7Ra expression by mRNA quantization. HIV-positive patients
had higher IL-7Ra mRNA levels than HIV-seronegative controls,
although this difference was not statistically significant (HIV
positive: 27.2641.27 IL-7Ra/10 ng GAPDH, HIV seronegative:
13.17623.57 ng IL-7Ra/10 ng GAPDH; p = .2). Interestingly,
INRs tended to have higher IL-7Ra mRNA levels than CF
patients and HIV-seronegative controls, although these difference
were not statistically significant (INRs: 41.33649.64 ng IL-7 Ra/
Figure 1. IL-7 plasma levels and IL-7Ra expression and production in peripheral blood. Levels of plasma IL-7 (A), IL-7Ra expression on
CD4+ and CD8+ T cells (B–C), and IL-7Ra production in peripheral blood (D) differ between HIV-positive HAART-treated subjects and HIV-seronegative
subjects. HIV-positive subjects were subdivided into two groups: subjects with low CD4+ counts and full suppression of viral replication
(immunological nonresponders, INRs) or patients with low CD4+ T-cell counts and elevated viral replication (complete failures, CFs). Compared to
HIV-seronegative controls, both INRs and CFs displayed augmented IL-7 plasma levels (A) and reduced proportions of IL-7Ra+ CD4+ and IL-7Ra+
CD8+ T cells (B and C). IL-7Ra production was measured in the peripheral blood of 10 unselected HIV-positive patients (6 INRs and 4 CFs) and 6 HIV-
seronegative subjects. Both INRs and CFs had significantly lower IL-7Ra mRNA levels than HIV-seronegative controls (D). Histogram heights and error
bars denote the mean and standard deviation, respectively, of the indicated parameters. *P,.05; **P,.01.
doi:10.1371/journal.pone.0015663.g001
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10 ng GAPDH, CFs: 662.16 ng IL-7 Ra/10 ng GAPDH; p = .3
for INRs vs. CFs; p = .5 for INRs vs. HIV-seronegative subjects;
p = .7 for CFs vs. HIV-seronegative subjects) (Figure 2C).
INRs had diminished levels of pStat5+CD4+ and Bcl-
2+CD8+ T cells following IL-7 stimulation
Given the higher IL-7 BM production despite low CD4+ counts
in INRs, we investigated the ex vivo response to IL-7.
Compared to HIV-seronegative subjects, INRs had higher
constitutive pStat5+CD4+ levels, whereas no differences were
shown between constitutive pStat5+CD8+ T cell levels
(pStat5+CD4+, INRs: 42.9643.5%, HIV-seronegative subjects:
10.766.8%, p = .06; pStat5+CD8+, INRs: 10.465.2%, HIV-
seronegative subjects: 8.467.1%, p = .3) (Figure 3A–B). Interest-
ingly, in INRs, IL-7 stimulation resulted in a nonsignificant
reduction in the proportion of pStat5+CD4+ T cells (20.2613.8%;
p = .2); the proportion of pStat5+CD4+ T cells tended to increase
in HIV-seronegative controls (16.6616.8%; p = .2) (Figure 3A).
Conversely, the proportion of pStat5+CD8+ T cells tended to
increase upon IL-7 stimulation in both patient groups, reaching
significance in INRs (INRs: 15.1610.7%, p = .04; HIV-seroneg-
ative subjects: 11.268.6%, p = .2) (Figure 3B).
No major differences were shown with respect to the proportion
of constitutive and IL-7-stimulated Bcl-2+CD4+ T cells (INRs:
2.963.22%, HIV-seronegative subjects: 2.662.5%, p = .9; IL-7-
mediated Bcl-2+CD4+, INRs: 2.662%, HIV-seronegative sub-
jects: 2.363.2%, p = .4) (Figure 3C). Conversely, compared to
HIV-seronegative subjects, INRs had lower constitutive and IL-7-
stimulated Bcl-2+CD8+ T-cell proportions (basal Bcl-2+CD8+ T
cells, INRs: 160.9%, HIV-seronegative subjects: 18.7619.1%,
p = .08; IL-7-induced Bcl-2+CD8+ T cells INRs: 0.760.6%, HIV-
seronegative subjects: 19.4621%, p = .04) (Figure 3D). No major
changes in the proportions of Bcl-2+ and CD8+ T cells were
observed following IL-7 stimulation in both patient groups (p = .2
and p = .9 for INRs and HIV-seronegative subjects, respectively)
(Figure 3D).
Discussion
The failure to gain CD4+ T cells and the time spent with
nonprotective CD4+ counts following HAART initiation are
associated with increased morbidity and mortality [26,27], making
the identification of alternative therapeutic approaches to promote
immune reconstitution essential. Recently, adjuvant recombinant
Figure 2. IL-7/IL-7Ra production by bone marrow stromal cells. IL-7 production was analyzed by (i) measuring IL-7 levels in the supernatants of
bone marrow mononuclear cells (BMMCs) from 20 unselected HIV-positive (10 INRs, 10 CFs) and 7 HIV-seronegative patients (A); and (ii) measuring IL-7
mRNA levels in BMMC-derived stromal cells from 12 unselected HIV-positive (8 INRs, 4 CFs) and 6 HIV-seronegative patients (B). IL-7Ra bone marrow
expression was measured in 10 unselected (6 INRs, 4 CFs) and 6 HIV-seronegative patients (C). IL-7/IL-7Ra bone marrow production in BMMCs differed
between HIV-positive HAART-treated subjects and HIV-seronegative subjects. HIV-positive subjects were subdivided into two groups: subjects with low
CD4+ counts and full suppression of viral replication (immunological nonresponders, INRs) and patients with low CD4+ T-cell counts and elevated viral
replication (complete failures, CFs). HIV-positive patients presented increased bone marrow production of IL-7 (A–B) and IL-7Ra (C). Separate analyses of
HIV-positive patients with different viro-immunological responses to HAART revealed a tendency for higher IL-7/IL-7Ra production in INRs compared to
other patients. Histogram heights and error bars denote the mean and standard deviation, respectively, of the indicated parameters.
doi:10.1371/journal.pone.0015663.g002
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human IL-7 (rhIL-7) was demonstrated to be effective in sustaining
CD4+ recovery in HIV-positive patients with different degrees of
immune deficiency [28,29]. Theoretically, due to its role as a
major regulator of T-lymphocyte homeostasis, IL-7 might be
particularly helpful in patients on HAART with persistent CD4+
lymphopenia, but the actual clinical value of IL-7 treatment in
these patients is questioned by the evidence of already elevated
endogenous IL-7 levels and reduced IL-7Ra expression
[16,17,28,29]. Therefore, we studied the bone marrow expression
and peripheral levels of IL-7 and IL-7Ra in HIV-positive patients
failing to recover CD4+ counts following initiation of HAART
with and without ongoing HIV viral replication.
In addition to confirming the elevated plasma IL-7 levels and
reduced IL-7Ra expression in circulating T cells in HIV-positive
individuals [10,20,30,31], we found that HIV-positive patients had
levels of bone marrow IL-7 production comparable to that of
healthy HIV-seronegative controls, with a trend for higher IL-7Ra
bone marrow expression compared to HIV-seronegative individ-
uals. As these findings were unexpected given the altered bone
marrow architecture and function resulting from HIV infection
[18,32,33,34,35], we separately analyzed HIV-positive individuals
to test the hypothesis that the bone marrow functions of subjects
differed according to the immune-virological response to HAART.
Despite a similar peripheral profile characterized by severe
CD4+ T-lymphopenia, heightened plasma IL-7 levels and reduced
IL-7Ra+CD4+/CD8+ T cell levels, the investigation of the bone
marrow compartment revealed divergent IL-7/IL-7R production
between INRs and CFs.
Patients with complete viro-immunological failure to HAART
displayed totally hampered production of IL-7 and IL-7Ra, likely
due to the complete loss of function of both bone marrow stromal
cells and peripheral lymphocytes. This finding is in line with
evidence suggesting that during the course of HIV infection, bone
marrow stromal auxiliary cells are persistently infected and
dysfunctional, impairing the marrow’s hematopoietic functions
[18,35,36]. Thus, elevated levels of circulating IL-7 in CFs likely
result from release by down-regulated cell-surface IL-7Ra levels
and not from increased production.
Our findings indicate the activity of opposing pathways in INRs, in
which stromal cell production of both IL-7 and IL-7Ra seems to be
elevated. Newly produced IL-7 might be released into the peripheral
blood and rapidly bind to cell-surface receptors, resulting in the
down-regulation of IL-7R in both CD4+ and CD8+ T cells [37].
With this perspective, equally reduced peripheral IL-7Ra
production and expression reflect dissimilar immune pathways.
In CFs, reduced peripheral IL-7Ra production and expression
Figure 3. IL-7 signaling in CD4+ and CD8+ T-cell subsets. IL-7 responsiveness was analyzed by measuring the constitutive and IL-7-induced
levels of phosphorylated signal transducer and activator of transcription 5 (pStat5) in CD4+ and CD8+ T cells from 8 unselected INRs compared to 10 HIV-
seronegative controls (A and B). INRs displayed a trend of higher constitutive percentages of CD4+pStat5+ T cells vs. HIV-seronegative controls.
Following IL-7 stimulation, the proportion of CD4+pStat5+ T cells tended to decrease in INRs (A), whereas no major changes were observed for
CD8+pStat5+ T cells (B). Constitutive and IL-7-induced expression levels of the anti-apoptotic molecule Bcl-2 were comparatively measured in seven
unselected INRs and six HIV-seronegative controls (C and D). No major differences in the proportions of CD4+Bcl-2+ T cells were observed between INRs
and HIV-seronegative controls (C), whereas INRs displayed significantly lower proportions of constitutive and IL-7-induced CD8+Bcl-2+ T cells (D). *P,.05.
doi:10.1371/journal.pone.0015663.g003
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might be due to IL-7Ra down-regulation driven by both elevated
circulating IL-7 levels, a direct viral effect [24,25], and HIV-
induced immune activation [22,23], whereas in INRs, reduced
peripheral IL-7Ra production and expression might result from
down-regulation of IL-7 receptor expression on CD4+ and CD8+
T cells following IL-7/IL-7R engagement [37].
Aiming to reconcile increased IL-7/IL-7R production with
persistent CD4+ T-lymphopenia in spite of removing the viral
challenge in INRs, we investigated the effect of reduced IL-7-
mediated signaling on T-lymphocyte homeostasis.
When compared to HIV-seronegative subjects, INRs displayed
higher constitutive pStat5 levels exclusively within CD4+ cells,
suggesting the persistence of HIV-induced up-regulation of Stat-
dependent signaling pathways despite viremia suppression [38,39].
However, IL-7 stimulation did not result in increased pStat5+ T-
cell proportions, confirming the reduced IL-7 responsiveness of the
peripheral T cells [16,17].
Our data suggest a model whereby CD4+ breakdown in the
absence of viral challenge is associated with compensatory
pathway(s) at the level of bone marrow stromal cells, resulting in
increased IL-7 production and activated Stat5 signaling, specifi-
cally in CD4+ T cells. It is tempting to speculate that this is a
compensatory pathway targeted to maintain peripheral T-
lymphocyte homeostasis. However, this supposition may be
inappropriate for continuous CD4+ exhaustion given the failure
of the IL-7-mediated peripheral signaling. One possibility is that
with the presence of such compensatory constitutive bone marrow
activation, the IL-7/IL-7R system might experience a ‘‘functional
exhaustion’’ with respect to the continuous demand provided by
peripheral T-lymphopenia, resulting in an overall desensitization
to further IL-7 stimulation.
Further studies on the regulatory pathways behind bone
marrow IL-7/IL-7R production and IL-7Ra-mediated signaling
in HIV/AIDS patients are needed to identify the most efficacious
clinical use of IL-7 in the (adjuvant) treatment of HIV-positive
patients.
Methods
Patients
Between October 2006 and June 2009, we performed a cross-
sectional study including 30 HIV-positive patients who were
followed at the Clinics of Infectious Diseases, ‘‘Luigi Sacco’’ and
‘‘San Paolo’’ Hospitals, University of Milan. Inclusion criteria
were stable HAART for at least six months and CD4+ #200/mL
over the last six months. Based upon virological response to six-
month HAART, patients were divided into two groups: INRs
(HIV-RNA#50 cp/ml) and CFs (HIV-RNA.1000 cp/ml).
As controls, we included 23 HIV-seronegative patients under-
going heart surgery.
All enrolled patients provided written informed consent
according to the Ethics Committees of our Institutions (Comitato
Etico, Ospedale ‘‘San Paolo’’ and Comitato Etico, Ospedale
‘‘Luigi Sacco’’, Milan, Italy). Both ethics committees specifically
approved this study.
IL-7 plasma concentration
IL-7 plasma concentrations were evaluated by ELISA (Quanti-
kine HS human IL-7; R&D, Milan, Italy) according to
manufacturer’s instructions.
Proportion of IL-7Ra+CD4+ and CD8+ T cells
The proportions of IL-7Ra (CD127)+ CD4+ T cells and CD8+
T cells were evaluated by flow cytometry (Coulter ESP; Beckman
Coulter, Hialeah, FL, USA). Briefly, 50 ml of fresh whole
peripheral blood was stained with fluorescently labeled antibodies
(fluorescein isothiocyanate [FITC], phycoerythrin [PE], and
phycoerythrin-cyanine 5 [PCy5]) (CD4+-FITC, Becton Dickinson,
San Jose, CA, USA; CD127+-PE and CD8+-PCy5, Coulter, FL,
USA). The following combination of monoclonal antibodies was
used: CD4+/CD8+/CD127+.
Cultures of bone marrow mononuclear cells (BMMCs)
Bone marrow aspirates were collected in EDTA. Ficoll-
separated BMMCs were cultured in 12-well plates in IMDM
medium containing 20% FCS, 100 UI/ml L-glutamine and
100 UI/ml penicillin-streptomycin at a concentration of 16106
cells/ml in a total volume of 3 ml/well.
Spontaneous IL-7 production by cultured BMMCs
BMMC cultures were incubated at 37uC in humidified air with
5% CO2 in the absence of stimuli to verify spontaneous
production of IL-7. Briefly, 24 hours after BMMC confluence,
supernatants were collected and IL-7 levels were measured by
ELISA (Quantikine HS human IL-7; R&D, Milan, Italy)
according to the manufacturer’s instructions.
IL-7 mRNA quantification from BMMC-derived stromal
cells (SCs)
Following BMMC culture as described above, nonadherent cells
were removed from cultures at specific intervals and were replaced
by 1000 ml of fresh supplemented IMDM. The cultures were
subsequently maintained until stromal confluence (3-4 weeks).
BMMC-derived SCs were collected by trypsinization and were
used to quantify IL-7 mRNA by real-time PCR. (i) RNA
extraction and reverse transcription. Total RNA was
isolated from BMMC-derived SCs (TRIzolH, Invitrogen, Carls-
bad, CA, USA). Potential genomic DNA contamination was
removed by incubation with RNase-free DNase I (Invitrogen,
Carlsbad CA, USA). From each sample, 4 to 8 ml of total RNA
(corresponding to about 250–500 ng) was used for cDNA synthesis
using the SuperScriptTM III First-Strand Synthesis System for RT-
PCR according to the manufacturer’s instructions (Invitrogen,
Carlsbad CA, USA). (ii) IL-7 mRNA quantification. A portion
of the cDNA mixture, corresponding to 1/3, 1/6, 1/21, or 1/210,
was subjected to SYBR green-based IL-7 and GAPDH mRNA
real-time PCR [40]. All amplifications were carried out on a 7500
Real-Time PCR System (Applied Biosystems, Foster City, CA,
USA) in a final volume of 50 ml with 100 nM of primers using the
Hot-Rescue Real-Time PCR Kit-SG (Diatheva s.r.l., Fano, Italy).
For IL-7 amplification, after one cycle at 95uC for 10 min, a two-
step PCR procedure was used consisting of 15 sec at 95uC and
45 sec at 68uC for 45 cycles. For GAPDH amplification, the
cycling conditions were 10 min at 95uC followed by 45 cycles of
15 sec at 95uC, 15 sec at 60uC and 35 sec at 72uC. To verify the
specificity of the PCR products, a dissociation curve analysis was
performed. He IL-7 and GAPDH primers amplified 157-bp and
176-bp cDNA fragments, respectively [41]. An external RNA
standard curve was used to quantify IL-7 mRNA levels. Ten-fold
serial dilutions from 107 to 103 of synthetic IL-7 RNA molecules
synthesized using the T7 RiboMAXTM Express Large-Scale RNA
Production System (Promega, Milan, Italy) were reverse tran-
scribed and amplified in the same run with unknown samples. For
data normalization, variable amounts (500-100-50-10-5 ng) of
mRNA (extracted from the PBMCs of healthy donors) were used
to generate a ‘‘gold standard’’ for GAPDH quantification. The
standard curves were created automatically by the Applied
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Biosystems software based upon threshold (Ct) values. A curve was
accepted when the slope was between -3.50 and -3.32 (93–100%
efficiency) and when the minimum value of the correlation
coefficient (R2) was 0.98. Data were expressed as IL-7 mRNA
copy number/10 ng GAPDH mRNA.
IL-7Ra mRNA quantification from PBMCs and BMMC-
derived SCs
Following RNA extraction/reverse transcription as described
above, detection of IL-7Ra mRNA in PBMCs and BMMC-
derived SCs was performed using the Assay on Demand Kit (ID:
Hs00233682_m1 Applied Biosystems). The ‘‘gold standard’’
described above was used for IL-7Ra and GAPDH mRNA
quantification. Data were expressed as ng IL-7Ra mRNA/10 ng
GAPDH mRNA.
Assessment of Stat5 phosphorylation
Ficoll-separated PBMCs were stained with fluorescently labeled
antibodies to cell surface markers (CD4+-FITC, CD8+-FITC,
Becton Dickinson, San Jose, CA, USA). PBMCs (26106 cells) were
incubated in medium (serum-free RPMI) with or without IL-7
(10 ng/mL) for 15 min at 37uC, washed, treated with FACS-lysing
solution (Becton Dickinson, San Jose, CA, USA), and stained with
anti-pStat5 perCP-Cy5.5 (BD Biosciences, San Jose, CA, USA) for
1 hour at RT in the dark. The following combinations of
monoclonal antibodies were used: CD4+/pStat5 and CD8+/pStat5.
Assessment of Bcl-2
Ficoll-separated PBMCs were stained with antibodies to cell
surface markers (CD4+-PE, CD8+-PE, Becton Dickinson, San
Jose, CA, USA). PBMCs (46106 cells) were incubated in medium
(serum-free RPMI) with or without IL-7 (10 ng/mL) for 24 hours
at 37uC, washed, treated by FACS-lysing solution (Becton
Dickinson, San Jose, CA, USA), and stained with anti-Bcl-2-
FITC (BD Biosciences, San Jose, CA, USA). The following
combinations of monoclonal antibodies were used: CD4+/Bcl-2
and CD8+/Bcl-2. pStat5/Bcl-2 analysis was conducted using a
BD FACSort (BD Biosciences, San Jose, CA, USA).
Statistics
Baseline categorical and continuous parameters were compared
using Fisher’s exact test, the Pearson chi-square test and Student’s t
test for independent samples, respectively. Variables for HIV-
positive patients and healthy controls were compared with
Student’s t test and the Mann-Whitney nonparametric U test.
The same variables were also compared between HIV-positive
subjects, INRs and CFs using one-way ANOVA followed by the
Games-Howell post hoc test for multiple comparisons. For
comparisons between the parameters of stimulated and unstimu-
lated cells, the Wilcoxon matched-pairs signed rank test was used.
Statistics were calculated using SPSS software (version 18.0).
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